Bloomberg: AstraZeneca Wants To Hold Another Vaccine Trial

AstraZeneca's vaccine trial initially reported 62% effectiveness with a full two-dose regimen and 90% with a dose and a half. However, the latter was due to a mistake in dosage concentration. The CEO plans to intentionally test the one and a half dosage to verify the 90% efficacy.

What was the reported effectiveness of AstraZeneca's vaccine when administered as a full two-dose regimen?

• 75%

• 90%

• 50%

• 62%

What was the effectiveness of the vaccine when a dose and a half was mistakenly given?

• 90%

• 85%

• 70%

• 62%

What caused the difference in the reported effectiveness of the vaccine?

• Mistake in dosage concentration

• Varying storage conditions

• Different age groups

• Incorrect trial data

What does AstraZeneca's CEO plan to do regarding the one and a half dosage?

• Reduce the dosage further

• Use it only in specific regions

• Administer it intentionally to test efficacy

• Discontinue its use

Why is AstraZeneca interested in testing the one and a half dosage again?

• To confirm the 90% efficacy

• To reduce production costs

• To increase the dosage further

• To comply with regulatory requirements